Table 1.
Demographics and baseline characteristics
| FIRMap (N = 24) | Conventional (N = 27) | All subjects (N = 51) | |
|---|---|---|---|
| Age (years), mean ± SD (n), median [IQR] | 62 ± 11.4 (24), 65 [33–78] | 65 ± 9.7 (27), 68 [48–78] | 63 ± 10.6 (51), 65 [33–78] |
| Sex, male | 14/24 (58.3%) | 15/27 (55.6%) | 29/51 (56.9%) |
| BMI (kg/m2), mean ± SD (n), median [IQR] | 27 ± 6.2 (24), 25 [18–39] | 28 ± 5.5 (26), 27 [19–43] | 28 ± 5.8 (50), 26 [18–43] |
| EHRA class | |||
| Class I | 2/24 (8.3%) | 0/27 (0.0%) | 2/51 (3.9%) |
| Class II | 8/24 (33.3%) | 7/27 (25.9%) | 15/51 (29.4%) |
| Class III | 14/24 (58.3%) | 18/27 (66.7%) | 32/51 (62.7%) |
| Class IV | 0/24 (0.0%) | 1/27 (3.7%) | 1/51 (2.0%) |
| Unknown | 0/24 (0.0%) | 1/27 (3.7%) | 1/51 (2.0%) |
| Medical history | |||
| Arterial hypertension | 11/20 (55.0%) | 13/21 (61.9%) | 24/41 (58.5%) |
| Coronary artery disease | 8/20 (40.0%) | 8/21 (38.1%) | 16/41 (39.0%) |
| Chronic renal insufficiency | 2/20 (10.0%) | 3/21 (14.3%) | 5/41 (12.2%) |
| Anti-arrhythmic use at baseline (%) | |||
| Amiodarone | 2/24 (8.3%) | 0/25 (0.0%) | 2/49 (4.1%) |
| Dronedarone | 0/24 (0.0%) | 0/25 (0.0%) | 0/49 (0.0%) |
| Flecainide | 4/24 (16.7%) | 7/25 (28.0%) | 11/49 (22.4%) |
| Propafenone | 1/24 (4.2%) | 0/25 (0.0%) | 1/49 (2.0%) |
| Sotalol | 0/24 (0.0%) | 2/25 (8.0%) | 2/49 (4.1%) |
| Left atrial diameter (mm); mean ± SD (n), median [IQR] | 44 ± 5.5 (24), 43 [36–55] | 44 ± 7.3 (23), 42 [32–67] | 44 ± 6.4 (47), 42 [32–67] |
IQR, interquartile range.